Fundamental Research on the Development of a New Technology of Direct Hemoperfusion Aiming to Remove Immunosuppressive Cytokines from the Blood of Cancer-Bearing Hosts

开发直接血液灌流新技术以去除癌症宿主血液中的免疫抑制细胞因子的基础研究

• 批准号: 14571152
• 负责人: UEDA Yuji
• 金额: $ 1.92万
• 依托单位: Kyoto Prefectural University of Medicine
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2002
• 资助国家: 日本
• 起止时间: 2002 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14571152/
• 关键词: Cancer Immunotherapy; Direct Hemoperfusion; Immunosuppressive Factor; Immunosuppressive Cytokine; TGFβ; VEGF; IL-6

We have done a fundamental research on the development of a new technology of direct hemoperfusion aiming to remove immunosuppressive cytokines from the blood of cancer-bearing hosts. Immunosuppressive substance adsorption (ISA) fiber was prepared by chemical modification of a polystyrene-based composite fiber. In brief, the composite fiber is treated with N-methylol-α-chloroacetamide in a mixture of sulfuric acid and nitrobenzene in the presence of paraformaldehyde. Sterile cylindrical plastic columns with a capacity of 2 ml were prepared by filling 0.4 g of ISA fiber. Tumor-bearing rats were made by implanting KDH-8 cells (hepatocelllar carcinoma) subcutaneously into the back of WKAH/Hm rats. Direct hemoperfusion of tumor-bearing rats using these columns significantly reduced the tumor growth and. prolonged the survival of them. These columns efficiently removed TGFb, VEGF, and IL-6 from the blood of tumor-bearing rats.

我们对直接血液灌流新技术的开发进行了基础研究，旨在去除荷癌宿主血液中的免疫抑制细胞因子。通过对聚苯乙烯基复合纤维进行化学改性，制备了免疫抑制物质吸附（伊萨）纤维。在多聚甲醛存在下，在硫酸和硝基苯的混合物中，用N-羟甲基-α-氯乙酰胺处理复合纤维。通过填充0.4g伊萨纤维制备容量为2 ml的无菌圆柱形塑料柱。通过将KDH-8细胞（肝细胞癌）皮下植入WKAH/Hm大鼠的背部制成荷瘤大鼠。使用这些柱对荷瘤大鼠进行直接血液灌流显著降低了肿瘤的生长。延长了他们的生存时间。这些柱有效地从荷瘤大鼠的血液中去除TGFb、VEGF和IL-6。

项目成果

上田祐二, 他: "新しい癌の体外循環治療技術の開発"医学のあゆみ. 208・12. 1012-1013 (2004)

Yuji Ueda等人：“癌症体外循环治疗新技术的开发”医学史208・1013（2004年）。

Yuji Ueda, Yoshiki Yamamoto, Hisakazu Yamagishi, Masaaki Shimagaki, Kazuo Teramoto: "New Technology of Direct Hemoperfusion for Cancer Therapy"Igaku-no-Ayumi (in Japanese). 208(12). 1012-1013 (2004)

Yuji Ueda、Yoshiki Yamamoto、Hisakazu Yamagishi、Masaaki Shimagaki、Kazuo Teramoto：“癌症治疗直接血液灌流新技术”Igaku-no-Ayumi（日语）。

Yuji Ueda, et al.: "Dendritic cell-based immunotherapy of cancer with the carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope."International Journal of Oncology. 24・4. 909-918 (2004)

Yuji Ueda 等人：“使用癌胚抗原衍生的 HLA-A24 限制性 CTL 表位进行基于树突状细胞的癌症免疫疗法”。《国际肿瘤学杂志》24·4（2004 年）。

Yuji Ueda, et al.: "Dendritic cell based immunotherapy of cancer with the carcinoembryonic antigen-derived, HLPvA24-restricted CTL epitope."International Journal of Oncology. 24. 909-918 (2004)

Yuji Ueda 等人：“使用癌胚抗原衍生的 HLPvA24 限制性 CTL 表位进行基于树突状细胞的癌症免疫疗法。”国际肿瘤学杂志。

上田祐二, 他: "新しい癌の体外循環治療技術の開発"医学のあゆみ. 208. 1012-1013 (2004)

Yuji Ueda 等人：“新型体外循环癌症治疗技术的开发”，医学史 208. 1012-1013 (2004)。